Implications of Cars Running on Oil Essay Example | Topics and Well Written Essays - 1250 words

Implications of Cars Running on Oil - Essay Example To save time, people head to their office on a personal car. This has, however, put much burden on economy and environment. While all the cars and transportation vehicles depend on oil, it is more likely that over the next decade the world will not have enough oil to fulfill the needs of cars. Â  Scientists have been looking for alternative fuel and combination of fuel which can reduce the burden on oil. There are many combinations of liquids that can be used along with oil to reduce the oil usage but the materials that can work well with oil in a mixture are all derived from food crops. This will lead to a burden on food crops and will affect the prices of the food items badly. Depending on food crops for food and as well as for transportation will put heavy burden and prices will soar so much that both will end up being not affordable. High prices will also increase the current food deficit all over the world. Many countries will not be able to provide the first basic necessity to their people which are food. This means adding a mixture of fuel to the equation and keeping the same ICE will not solve the problem over the next decades, it will only worsen it. This means that the initiative taken to completely eliminate the oil from the equation can solve the problem. Â  Many companies are working to invent batteries that can support EV (Electronic Vehicles), an idea which was dropped in the 19th century due to the dependence of EV on batteries which can only last 50 miles and needed replacement of battery very soon. There are also manufacturers who are reducing the car weight by replacing steel which helps in increasing efficiency of the cars running on any other fuel or material other than oil.

Company Data Research Paper Example | Topics and Well Written Essays - 1000 words

Company Data - Research Paper Example 79). Take Pfizer, one of the top ten largest drug suppliers in the world that belongs to big pharma. It is considered to be the most profitable as it ranked number one in the worldwide sales on drugs designated as prescription (Clinton & Mozeson, 2010, p. 70). The company is also the highest spender in terms of research and development (R&D), and in merger and acquisition activities. However, some surprising facts have been discovered during the Pharm Exec’s industry audit and Stealth pharma audit. The main focus of this paper is to review pharmaceutical company data between the audit of stealth pharma and big pharma such as Pfizer. After the gathering of data, surprising facts will be gathered and developed analyses. Company Data Pharmaceutical companies decided to venture in other parts of the world because of higher opportunity and promised benefits that would surely outweigh the difficulty of globalization. Japan, Western Europe, and North America are among the countries i n the world that are high in pharmaceutical sales (Campbell, 2008, p. 16). The current trend of pharmaceutical companies nowadays is merger and acquisition which is not only practiced by big pharma but also to stealth pharma in order for them to expand their sales, market capitalization, and market share. Pfizer is one of the big pharmas that acquired several companies for the past ten years. For the year 2001, it acquired its direct competitor Warner-Lambert for $90 billion, and by 2003 the company decided to merge with Pharmacia for $60 billion in order to reduce its R&D cost (Lawson, Hatch, & Desroches, 2008, p. 157). Recently, the company has acquired Wyeth for $68 billion; this is to back up the company’s dropping of revenue caused by patent expiration and portfolio diversification (â€Å"Pfizer,† 2009). More companies believed that through pharmerging, their market share would increase as competition has been reduced for companies that merged and acquired are dir ect competitors in the market. On the other hand, it has been manifested that big pharma’s expenses on R&D (approximately $304 billion) are much higher compared to the disbursement of stealth pharma which is only $157 million (Trombetta, 2007). From this point of view, it is expected that big pharma would gain higher revenues in comparison to the anticipation of stealth pharma. Usually, large pharmaceutical companies in America are required to spend more on R&D as part of government regulations in exchange with the granting of patent and trademarks that give the company an exclusive right to manufacture and sell the drugs. For instance, â€Å"Pfizer spent almost $7.6 billion on R&D for drugs and slightly over $2 billion on plants and equipments† and in exchange, the company’s drugs are under the U.S. patent protection (Siegel, 2008, p. 109). Three Surprising Facts A professor from Harvard Business School, Gary Pisano said that, â€Å"The record of big mergers a nd acquisitions in big pharma has not just been good. There’s just been an enormous amount of shareholder wealth destroyed† (as cited in Karnitschnig & Rockoff, 2009). It had been a surprised fact that merging among stealth pharma had been successful considering that biotechnology companies have increased in numbers and they have managed to be at the top twenty firms. It had been interesting to discover that